Close Menu

NEW YORK (GenomeWeb) – Precision oncology diagnostic firm MolecularMD has received authorization from the US Food and Drug Administration for a test to help physicians determine whether a patient with chronic myeloid leukemia (CML) can stop treatment with Novartis' drug Tasigna (nilotinib). 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

NPR reports that graduate students in the US are helping with SARS-CoV-2 testing.

Politico reports President Donald Trump has signed the $2 trillion coronavirus relief package.

A new analysis finds that peer review improves the quality of preprints just a little bit, according to ScienceInsider.

In PLOS this week: epigenetic drug triggers anti-viral activity, viral diversity among individuals with HIV experiencing virological failure, and more.